19.26
+3.49%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About GH Research
Its shares trade under the ticker GHRS. It has been listed since 25 June 2021.
GH Research Plc operates as a holding company, which engages in the provision of biopharmaceutical products and services. The company is headquartered in Dublin, Leinster. The company went IPO on 2021-06-25. The firm is engaged in offering treatment for psychiatric and neurological disorders. The firm's pipeline includes GH001, GH002 and GH003. The firm focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, it has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). GH002 is its 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. GH003 is its 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 25 Jun 2021
- Employees
- 73
- Head office
- JOSHUA DAWSON HOUSE, DUBLIN 2, L2, D02 RY95
- Incorporated in
- L2
- Classification
- Pharmaceutical Preparations
- Filer status
- Accelerated filer<br>Emerging growth company
Leadership
Pay as last reported
- Mr. Florian SchonhartingNon-Executive Chairman of the Board, since 2018
- Dr. Velichka ValchevaChief Executive Officer
- Mr. Michael ForerNon-Executive Independent Vice Chairman of the Board
- Ms. Julie RyanVice President - Finance
- Mr. Magnus HalleManaging Director, Ireland
- Mr. Dermot HanleyNon-Executive Independent Director
- Dr. Duncan MooreNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- GH001 completed two Phase 1 trials and a Phase 1/2 trial for TRD treatment in Dublin.
- GH002 advanced to pre-clinical development for injectable 5-MeO-DMT therapies.
- GH003 focuses on intranasal administration of 5-MeO-DMT for psychiatric disorders.
Weaknesses
- GH Research employs only 32 full-time employees in Dublin, Ireland.
- The company has no revenue from its biopharmaceutical products as of 2021.
- GH001, GH002, and GH003 are still in early development stages.
Opportunities
- GH001's inhalation approach for 5-MeO-DMT could expand treatment options for TRD patients.
- GH002's injectable formulation may attract partnerships for clinical trials in Europe.
- GH003's intranasal method offers potential for faster patient adoption in psychiatric care.
Threats
- Competition from other psychiatric treatment providers in the Health Care sector.
- Regulatory delays in approving 5-MeO-DMT therapies for TRD treatment.
- Limited funding for early-stage biopharmaceutical development in Ireland.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.